S&P 500   3,853.35 (-0.05%)
DOW   30,949.25 (-0.03%)
QQQ   329.51 (+0.43%)
AAPL   142.36 (-0.39%)
MSFT   233.54 (+1.75%)
FB   284.53 (+2.35%)
GOOGL   1,907.93 (+0.72%)
AMZN   3,326.00 (+0.97%)
TSLA   884.81 (+0.46%)
NVDA   541.70 (-0.81%)
BABA   262.92 (+0.59%)
CGC   35.10 (+6.65%)
GE   11.53 (+4.91%)
MU   81.36 (+0.10%)
AMD   95.05 (+0.98%)
NIO   59.27 (-1.20%)
T   29.25 (+0.48%)
F   11.31 (+0.18%)
ACB   10.58 (+4.13%)
BA   202.97 (-0.19%)
DIS   169.70 (-1.27%)
NFLX   565.42 (+1.55%)
GILD   67.42 (-1.09%)
S&P 500   3,853.35 (-0.05%)
DOW   30,949.25 (-0.03%)
QQQ   329.51 (+0.43%)
AAPL   142.36 (-0.39%)
MSFT   233.54 (+1.75%)
FB   284.53 (+2.35%)
GOOGL   1,907.93 (+0.72%)
AMZN   3,326.00 (+0.97%)
TSLA   884.81 (+0.46%)
NVDA   541.70 (-0.81%)
BABA   262.92 (+0.59%)
CGC   35.10 (+6.65%)
GE   11.53 (+4.91%)
MU   81.36 (+0.10%)
AMD   95.05 (+0.98%)
NIO   59.27 (-1.20%)
T   29.25 (+0.48%)
F   11.31 (+0.18%)
ACB   10.58 (+4.13%)
BA   202.97 (-0.19%)
DIS   169.70 (-1.27%)
NFLX   565.42 (+1.55%)
GILD   67.42 (-1.09%)
S&P 500   3,853.35 (-0.05%)
DOW   30,949.25 (-0.03%)
QQQ   329.51 (+0.43%)
AAPL   142.36 (-0.39%)
MSFT   233.54 (+1.75%)
FB   284.53 (+2.35%)
GOOGL   1,907.93 (+0.72%)
AMZN   3,326.00 (+0.97%)
TSLA   884.81 (+0.46%)
NVDA   541.70 (-0.81%)
BABA   262.92 (+0.59%)
CGC   35.10 (+6.65%)
GE   11.53 (+4.91%)
MU   81.36 (+0.10%)
AMD   95.05 (+0.98%)
NIO   59.27 (-1.20%)
T   29.25 (+0.48%)
F   11.31 (+0.18%)
ACB   10.58 (+4.13%)
BA   202.97 (-0.19%)
DIS   169.70 (-1.27%)
NFLX   565.42 (+1.55%)
GILD   67.42 (-1.09%)
S&P 500   3,853.35 (-0.05%)
DOW   30,949.25 (-0.03%)
QQQ   329.51 (+0.43%)
AAPL   142.36 (-0.39%)
MSFT   233.54 (+1.75%)
FB   284.53 (+2.35%)
GOOGL   1,907.93 (+0.72%)
AMZN   3,326.00 (+0.97%)
TSLA   884.81 (+0.46%)
NVDA   541.70 (-0.81%)
BABA   262.92 (+0.59%)
CGC   35.10 (+6.65%)
GE   11.53 (+4.91%)
MU   81.36 (+0.10%)
AMD   95.05 (+0.98%)
NIO   59.27 (-1.20%)
T   29.25 (+0.48%)
F   11.31 (+0.18%)
ACB   10.58 (+4.13%)
BA   202.97 (-0.19%)
DIS   169.70 (-1.27%)
NFLX   565.42 (+1.55%)
GILD   67.42 (-1.09%)
Log in
NYSE:ABT

Abbott Laboratories Stock Forecast, Price & News

$114.60
-0.12 (-0.10 %)
(As of 01/26/2021 10:57 AM ET)
Add
Compare
Today's Range
$113.82
Now: $114.60
$115.38
50-Day Range
$106.32
MA: $109.51
$112.95
52-Week Range
$61.61
Now: $114.60
$115.40
Volume53,856 shs
Average Volume4.89 million shs
Market Capitalization$203.11 billion
P/E Ratio60.64
Dividend Yield1.60%
Beta0.83
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. Its Nutritional Products segment provides pediatric and adult nutritional products. The company's Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. This segment also provides glucose and blood glucose monitoring systems. Abbott Laboratories has an agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions. The company was founded in 1888 and is headquartered in North Chicago, Illinois.
Abbott Laboratories logo

MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

12th out of 1,922 stocks

Pharmaceutical Preparations Industry

6th out of 771 stocks

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100
Employees107,000
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$5.14 per share
Book Value$17.70 per share

Profitability

Net Income$3.69 billion

Miscellaneous

Outstanding Shares1,772,362,000
Market Cap$203.11 billion
Next Earnings Date1/27/2021 (Confirmed)
OptionableOptionable
$114.60
-0.12 (-0.10 %)
(As of 01/26/2021 10:57 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock been impacted by Coronavirus?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABT stock has increased by 46.4% and is now trading at $114.33.
View which stocks have been most impacted by COVID-19
.

Is Abbott Laboratories a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Abbott Laboratories stock.
View analyst ratings for Abbott Laboratories
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Abbott Laboratories?

Wall Street analysts have given Abbott Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Abbott Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Robert Ford's approval rating as Abbott Laboratories' CEO?

183 employees have rated Abbott Laboratories CEO Robert Ford on Glassdoor.com. Robert Ford has an approval rating of 89% among Abbott Laboratories' employees.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Abbott Laboratories
.

How can I listen to Abbott Laboratories' earnings call?

Abbott Laboratories will be holding an earnings conference call on Wednesday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, October, 21st. The healthcare product maker reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.08. The healthcare product maker had revenue of $8.85 billion for the quarter, compared to the consensus estimate of $8.53 billion. Abbott Laboratories had a net margin of 10.50% and a trailing twelve-month return on equity of 18.19%. The business's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.84 EPS.
View Abbott Laboratories' earnings history
.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, December 11th. Shareholders of record on Friday, January 15th will be paid a dividend of $0.45 per share on Tuesday, February 16th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.57%. The ex-dividend date is Thursday, January 14th. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.36.
View Abbott Laboratories' dividend history
.

Is Abbott Laboratories a good dividend stock?

Abbott Laboratories pays an annual dividend of $1.80 per share and currently has a dividend yield of 1.60%. Abbott Laboratories has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Abbott Laboratories is 55.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.10% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.
View Abbott Laboratories' dividend history.

What price target have analysts set for ABT?

16 Wall Street analysts have issued 1-year price objectives for Abbott Laboratories' stock. Their forecasts range from $94.00 to $130.00. On average, they anticipate Abbott Laboratories' share price to reach $115.69 in the next year. This suggests a possible upside of 1.2% from the stock's current price.
View analysts' price targets for Abbott Laboratories
or view Wall Street analyst' top-rated stocks.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T), Pfizer (PFE), The Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), The Home Depot (HD) and Verizon Communications (VZ).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:
  • Mr. Miles D. White M.B.A., Exec. Chairman (Age 66, Pay $6.97M)
  • Mr. Robert B. Ford, CEO, Pres, COO & Director (Age 47, Pay $2.63M)
  • Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 42, Pay $1.67M)
  • Ms. Lisa D. Earnhardt, Exec. VP of Medical Devices (Age 51, Pay $1.33M)
  • Mr. Robert E. Funck Jr., Exec. VP of Fin. & CFO (Age 60)
  • Mr. Scott Michael Leinenweber, VP of Investor Relations, Licensing & Acquisitions (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • James E. Young, VP and Chief Ethics & Compliance Officer
  • Ms. Melissa Brotz, VP of Public Affairs & Corp. Marketing
  • Ms. Elaine R. Leavenworth, Sr. VP and Chief Marketing & External Affairs Officer (Age 62)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include New York State Teachers Retirement System (0.14%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.10%), Strs Ohio (0.08%), Nisa Investment Advisors LLC (0.04%), Gateway Investment Advisers LLC (0.04%) and Welch & Forbes LLC (0.04%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories
.

Which major investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Strs Ohio, Crossmark Global Holdings Inc., Hexavest Inc., Gateway Investment Advisers LLC, Rhenman & Partners Asset Management AB, New York State Teachers Retirement System, and Avantax Advisory Services Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Phebe N Novakovic, Philip P Boudreau, Randel William Woodgrift, Robert E Funck, Roger Bird, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories
or view top insider-selling stocks.

Which major investors are buying Abbott Laboratories stock?

ABT stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Locust Wood Capital Advisers LLC, Liberty Capital Management Inc., Tandem Investment Advisors Inc., Journey Advisory Group LLC, Hendley & Co. Inc., IFM Investors Pty Ltd, and Bath Savings Trust Co. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories
or or view top insider-buying stocks.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $114.33.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $202.63 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.